We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single Tube PCR Identifies Aneuploidies in Embryos

By LabMedica International staff writers
Posted on 25 Jun 2012
A novel test is being developed for genetic abnormalities during pregnancy.

A single tube multiplex polymerase chain reaction (PCR) starting from fetal DNA isolated from the mother’s blood, allows the identification of copy number variations (or aneuploidies) of chromosomes 21, 18, 13, X and Y. More...
Such variations cause genetic diseases like Down’s syndrome, Edward’s syndrome, Patau syndrome, triple X syndrome, and Klinefelter’s syndrome.

The test needs only a blood sample, in contrast to the invasive screening methods in use today. It will be based on Multiplicom’s (Niel, Belgium) proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

The noninvasive aneuploidy testing (NIAT) is a novel approach that aims to replace the 250,000 invasive procedures such as amniocentesis and chorionic villus sampling performed annually in Europe. These procedures are time consuming and carry a significant risk of complications during pregnancy. NIAT is not only rapid and safe but is designed to have predictive power superior to that of conventional prenatal testing methods.

Multiplicom, a molecular diagnostics company specializing in the design, development, production, and commercialization of innovative molecular genetic tests based on massively parallel sequencing, has been awarded a USD 260,000 grant from the Flemish agency for Innovation by Science and Technology (IWT).

The grant is intended to support the development of a novel test for genetic abnormalities during pregnancy that needs only a blood sample, in contrast to the invasive screening methods in use today. The test will be based on Multiplicom’s proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

Dr. Dirk Pollet, CEO of Multiplicom, said: “This grant is a strong endorsement of our MASTR technology. It will allow Multiplicom to develop a new assay that will help physicians and patients enhance prenatal medical care while cutting costs. In the future, we see this test entirely replacing current invasive techniques.”

Subsequent validation studies will be conducted in close collaboration with hospitals throughout Europe. Multiplicom aims to make the test available to all accredited genetics labs as part of its drive to make personalized healthcare available to all.

Related Links:

Multiplicom




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.